GLP-1 Revolution
by Amaltash Advisors LLC
$462.40
+6.79% past month
Nov 16, 2026
$462.32-0.72%
Amgen closed down 0.72%, a smaller decline than its peer group. Comparable listed companies in biological products fell 1.96% on average, and all 6 of the 6 fell .
Nov 13, 2026
$465.67-0.30%
Amgen closed down 0.30%, a smaller decline than the cohort's. Comparable listed companies in biological products moved -1.15% on average, with 4 of 6 falling and 2 rising .
Nov 12, 2026
$467.06-0.22%
Amgen closed down 0.22%, while comparable biological products companies fell 2.61% on average, with all 6 lower . Amgen fell far less than the cohort did .
Nov 11, 2026
$468.11+0.62%
Amgen announced positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren's disease, according to PR Newswire . Seeking Alpha described the shares as slipping after the late-stage data . The stock closed up 0.62%, while comparable listed companies in biological products fell 0.76% on average, with 3 of 6 falling and 3 rising .
Nov 10, 2026
$465.23+0.00%
Amgen closed unchanged at +0.00%, while comparable biological products companies fell 1.91% on average, with four of six declining . The flat close was therefore not shared by the cohort.
Nov 9, 2026
$465.23+1.04%
Comparable biological products companies rose 3.28% on average, with all 6 of 6 rising . AMGN's 1.04% gain came alongside that cohort advance, though it was smaller than the cohort average .
Nov 6, 2026
$460.42+0.03%
Amgen closed almost unchanged, up 0.03%, while comparable biological products companies rose 3.20% on average, with 5 of 6 higher . The move was therefore not shared by the cohort. Seeking Alpha reported that Democratic lawmakers were seen planning probes into Trump drug pricing deals .
Closing prices for AMGN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, Amgen Inc. is 3.4% below its 52-week high. Its largest decline in the period shown was -26.7% (Nov 8, 2022 to Jun 1, 2023).
As of Nov 16, 2026, Amgen Inc. closed 3.4% below its 52-week closing high, set on Nov 4, 2026.
Amgen Inc. fell 26.7% from Nov 8, 2022 to Jun 1, 2023, close to close, the largest decline in daily data since Nov 18, 2021. It closed back above that high on Jan 2, 2024.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Nov 18, 2021 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in Amgen Inc. (AMGN) 10 years ago, at the Nov 30, 2016 close, would be worth about $3,209 today, based on the Nov 16, 2026 close — a gain of $2,209 (+220.9%), dividends not included. Along the way it fell as much as 28.1% from a high, between Jan 2021 and Nov 30, 2021. Before Nov 2021 this uses monthly highs and lows.
Return calculator
Worth today, at the Nov 16, 2026 close
$26,857
+$13,957 · +108.2%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of AMGN's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell AMGN.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 5 years that's 1,200 coffees, or $6,000.
The same $100 a month put into AMGN since November 2021 would be worth $9,875 today.
That's 1,975 coffees. Make it a large.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | AMGN price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $345.46 | $1,338 | $13,383 | +33.8% |
| 3 years | Nov 30, 2023 | $269.64 | $1,715 | $17,146 | +71.5% |
| 5 years | Nov 30, 2021 | $198.88 | $2,325 | $23,246 | +132.5% |
| 10 years | Nov 30, 2016 | $144.07 | $3,209 | $32,090 | +220.9% |
$10,000 invested in Amgen Inc. (AMGN) at the Nov 30, 2016 close would have been worth about $32,090 at the Nov 16, 2026 close — a gain of $22,090 (+220.9%), dividends not included.
AMGN closed at $144.07 on Nov 30, 2016 (split-adjusted). It closed at $462.32 on Nov 16, 2026.
Putting $100 into AMGN at each month-end close from Nov 30, 2016 — 120 purchases, $12,000 in total — would have been worth about $23,969 at the Nov 16, 2026 close: a gain of $11,969 (+99.7%), dividends not included.
AMGN closed at $462.32 on Nov 16, 2026. A year earlier it closed at $336.74 on Nov 14, 2025, so it is up 37.3% over that year. Five years earlier it closed at $206.97 on Oct 29, 2021 (up 123.4% since then). Its highest close in the year to Nov 16, 2026 was $478.48 on Nov 4, 2026, and its lowest was $313.85 on Dec 9, 2025. These are split-adjusted closing prices; dividends are not included.
AMGN last closed at $462.32 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $336.74 on Nov 14, 2025 to $462.32 on Nov 16, 2026, it was up 37.3%. Over five years, from $206.97 on Oct 29, 2021 to $462.32 on Nov 16, 2026, it was up 123.4%. These are split-adjusted closing prices; dividends are not included.
As of Nov 16, 2026, Amgen Inc. had a market value (market cap) of about $251.9 billion and a price-to-earnings (P/E) ratio of 25.
Amgen discovers, makes and sells medicines for serious diseases. Its medicines help with swelling diseases, cancer, weak bones, and heart problems.
We do not tell anyone whether to buy or sell AMGN, and past results do not predict future results. Its largest fall from a high since Nov 18, 2021 was 26.7%, from $292.39 on Nov 8, 2022 to $214.27 on Jun 1, 2023. A single stock can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of AMGN's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell AMGN.
Try the full investment calculatorThese strategies on Amaltash hold AMGN today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC
by Amaltash Advisors LLC
This strategy bets on the booming weight-loss and metabolic health revolution — and it goes far beyond just the blockbuster drug makers you've heard about on the news. It builds a diversified basket across the entire ecosystem: companies developing next-generation obesity and diabetes treatments, the diagnostic labs helping doctors identify and monitor patients, the device makers tracking metabolic health, the clinics and care delivery platforms scaling treatment access, and even the insurers reshaping how metabolic disease is covered and reimbursed. The strategy focuses exclusively on companies that have already shown sustained upward price momentum over recent years — it's not trying to pick speculative moonshots, but rather ride names that the market has already started rewarding. The basket rotates and rebalances to keep exposure fresh, leaning into the strongest performers while trimming names that lose their footing. It's long-only and growth-oriented, meaning it profits when these companies rise in value — it does not short or hedge. The personality is opportunistic but not reckless: a built-in drawdown guardrail is designed to protect the portfolio if the sector hits a rough patch, targeting a maximum loss limit so a bad quarter doesn't wipe out a good year. Imagine this scenario: A major insurer announces it will cover GLP-1 treatments broadly. Drug makers surge, but so do the glucose monitors, the telehealth obesity clinics, and the cardiac device companies treating downstream complications. This strategy is already holding across all of those layers — capturing the wave rather than just one drop of it.
View strategy →